Arginine silicate inositol complex and use thereof

Details Arginine silicate inositol complex and use thereof Arginine silicate inositol complex and use thereof

2005-06-06

2009-08-18

Henley, III, Raymond J (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Radical -xh acid, or anhydride, acid halide or salt thereof...

C514S023000

Reexamination Certificate

active

07576132

ABSTRACT:
A method for preventing and treating a variety of disease states and disorders is provided, comprising the administration of an arginine silicate inositol complex to an individual in the presence of medical therapy or absence of medical therapy. Examples of said disease states and disorders include bone and cartilage disorders and cardiovascular disease and its associated micro and macro vascular complications including infections and inflammation of all these diseases in combination or without. Advantageously, the amount of arginine silicate inositol complex administered per day is between about 2 mg/Kg body weight to 2,500 mg/Kg body weight or from a low dose to a higher dose to observe normal metabolic functions and healthy and the delivery is parenteral, oral or intravenous or topical by solid or liquid or both.

REFERENCES:
patent: 3337403 (1967-08-01), Zentner
patent: 4297349 (1981-10-01), Barcza
patent: 4385052 (1983-05-01), Zackheim et al.
patent: 4573996 (1986-03-01), Kwiatek et al.
patent: 4597961 (1986-07-01), Etscorn
patent: 4839174 (1989-06-01), Baker et al.
patent: 4908213 (1990-03-01), Govil et al.
patent: 4943435 (1990-07-01), Baker et al.
patent: 5217997 (1993-06-01), Levere et al.
patent: 5250569 (1993-10-01), Godfrey
patent: 5284657 (1994-02-01), Lu et al.
patent: 5288497 (1994-02-01), Stanley et al.
patent: 5622980 (1997-04-01), Caldwell et al.
patent: 5662920 (1997-09-01), Santus
patent: 5707970 (1998-01-01), McCarty
patent: 5716610 (1998-02-01), Jack et al.
patent: 5763392 (1998-06-01), Hansen et al.
patent: 5763496 (1998-06-01), Holland
patent: 5804203 (1998-09-01), Hahn et al.
patent: 6066659 (2000-05-01), Speck
patent: 6123936 (2000-09-01), Platz et al.
patent: 6132394 (2000-10-01), Lankinen
patent: 6156735 (2000-12-01), McCarty
patent: 6182655 (2001-02-01), Keller et al.
patent: 6298847 (2001-10-01), Datta et al.
patent: 6344444 (2002-02-01), McCarty
patent: 6387394 (2002-05-01), Baichwal et al.
patent: 6418926 (2002-07-01), Chawla
patent: 6803456 (2004-10-01), Kuhlmann
patent: 2002/0068365 (2002-06-01), Kuhrts
patent: 2745498 (1997-09-01), None
patent: 2610522 (1998-08-01), None
patent: WO 98/34647 (1998-08-01), None
patent: 00/45651 (2000-08-01), None
patent: 02/28379 (2002-04-01), None
Bassler, T.J. (1978) Hard water, food fiber, and silicon. British Medical Journal. 1:919.
Bonnefont-Rkousselot (2002) Glucose and reactive oxygen species. Curr. Opin. Clin. Nutr. Metab. Care 5:561-568.
Calver, et al. (1992) Effect of local intra-arterial NG-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J. of Hypertension. 10:1025-1031.
Carlisle, E.M. (1972) Silicon: An essential element for the chick. Science 178:619-621.
Carlisle, E.M. (1976) In vivo requirement for silicon in articular cartilage and connective tissue formation in the chick. J. Nutr. 106:478-484.
Carlisle, et al. (1978) A requirement for silicon for bone growth in culture. Fed. Proc. 37:404.
Carlisle, et al. (1980) A silicon requirement for normal growth of cartilage in culture. Fed. Proc. 39:787.
Carlisle, E.M. (1980) Biochemical and morphological change associated with long bone abnormalities in silicon deficiency. J. Nutr. 110:1046-1055.
Chen, P.Y., et al. (1991) L-arginine abrogates salt-sensitive hypertension in dahl/rapp rats. J. Clin. Invest. 88:1559-1567.
Clarkson, et al. (1996) Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J. Clin. Invest. 97(8):1989-1994.
Clowes, et al. (1977) Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature. 265:625-626.
Cooke, et al. (1994) Is NO an endogenous antiatherogenic molecule. Arteriosclerosis and Thrombosis. 14(5):653-655.
Creager, et al. (1992) L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J. Clin. Invest. 90:1248-1253.
Curtis, et al. (1997) Nitric oxide supplementation or synthesis block—which is the better approach to treatment of heart disease?, Trends in Pharmacological Sciences. 18(7):239-244.
Drexler, et al.(1991) Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet. 338:1546-1550.
Edelman, et al. (1990) Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury. Proc. Natl. Acad. Sci. USA. 87:3773-3777.
Eisinger et al. (1993) Effects of silicon, fluoride, etidronate and magnesium on bone mineral density: a retrospective study. Magnisium Research. 6(3):247-249.
Garson, et al. (1971) Organosilicon entities as prophylactic and therapeutic agents. J. of Pharmaceutical Sciences. 60(8):1113-1127.
Guyton, et al. (1980) Inhibition of rat aterial smooth muscle cell proliferation by heparin. Circ. Res. 46:625-634.
Harrison's Principles of Internal Medicine, 13thedition, vol. 2, Isselbacher et al. (eds.), published 1994 by McGraw-Hill in 1994, p. 1321.
Hott et al. (1993) Short-term effects of organic silicon on trabecular bone in mature ovariectomized rats. Calcif. Tissue Int. 53:174-179.
Laurant, et al. (1995) Dietary L-arginine attenuates blood pressure in mineralocorticoid-salt hypertensive rats. Clin. and Exper. Hypertension 17(7):1009-1024.
Loeper, et al. (1979) The antiatheromatous action of silicon. Atherosclerosis 33:397-408.
Loeper, et al. (1978) The physiological role of the silicon and its antiatheromatous action, in biochemistry of silicon and related problems. Bendz G. et al. Eds. Plenum Press, NY 281-296.
Luscher, T.F. (1991) Endothelium-derived nitric oxide: The endogenous nitrovasodilator in the human cardiovascular system. Eur. Heart J., 12(Suppl. E):2-11.
Maulik, et al. (1995) Nitric oxide signaling in ischemic heart. Cardiovasc. Res. 30(4):593-601.
McPherson et al. (2002) Superoxide activates constitutive nitric oxide synthase in a brain particulate fraction. Biochemical and Biophysical Research Communications. 296:413-418.
Moncada, et al. (1993) The L-arginine-nitric oxide pathway. The New. Engl. J. of Med. 329(27):2002-2012.
Parr, R.M. (1980) Silicon, wine, and the heart. Lancet p. 1087.
Rubanyi, M.D., Ph.D. (1991) endothelium-derived vasoactive factors in health and disease, in cardiovascular significance of endothelium-derived vasoactive factors. Rubanyi, G.M., ed., Futura Publishing Company, Inc., NY xi-xix.
Schwarz,et al. (1972) Growth-promoting effects of silicon in rats. Nature. 239:333-334.
Schwarz, K., Silicon (1977) Fiber, and atherosclerosis. Lancet. 454-457.
Schwarz,et al. (1977) Inverse relation of silicon in drinking water and atherosclerosis in finland. Lancet 538-539.
Schwarz, K. (1978) Significance and functions of silicon in warm-blooded animals, in biochemistry of silicon and related problems. Bendz, G. et al., Eds., Plenum Press, NY 207-230.
Svehla, G. (1979) Reaction of silicates. Vogels Textbook of Macro and Semimicro Qualitative Inorganic Analysis 5thEdition, Longman, London pp. 350-353.
Tsao, et al. (1994) Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine. Circulation 89(5):2176-2182.
Wang et al. (1999) Effects of nitric oxide synthase inhibitors on systemic hypotension, cytokines and inducible nitric oxide synthase expression and lung injury following indotoxin administration in rats. J. Biomed. Sci. 6:28-35.
Miller, et al. “Practical Clinical Application of Biochemical Markers of Bone Turnover.” Journal of Clinical Densitometry. 2(3):323-342 (1999).
Partial European Search Report for European Application No. 03793307.4, dated Aug. 2, 2007.
Calles-Escandon et al. “Diabetes and endothelial dysfunction: A clinical perspective.” Endocrine Reviews. 22(1):36-52 (2001).
Kelly et al. “Insulin resistance: lifestyle and nutritional interventions.” Alternative Medicine Review. 5 (2):109-132 (2000).
Van Lente. “Markers of inflammation as predictors in cardiovascular disease.” Clinica Chimica Acta. 293:31-52 (2000).
Proctor et al. “A novel complex of arginine-silicate improved micro and macrovascular function and inhibit

Affiliated with

Also associated with

Rating

Arginine silicate inositol complex and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Arginine silicate inositol complex and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arginine silicate inositol complex and use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4086594